Gemmus Pharma Inc., a biotechnology company, develops therapeutics for the treatment of influenza and other infectious diseases. The firm was founded to commercialize in-licensed technology from a major pharmaceutical company. Using a novel, host-directed approach, Gemmus target the underlying cause of debilitating symptoms associated with influenza and 'influenza-like-illness' (ILI) by modulating the natural immune response to the disease. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. In 2014, Gemmus indicated plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections.